Cytognos Competitors and Similar CompaniesClear all

Cytognos's competitors and similar companies include Bioclinic Group, Exact Sciences, i2a and Trinity Biotech.

	Cytognos Cytognos is a clinical flow cytometry diagnostic company.	Bioclinic Group Bioclinic is a company that operates a network of medical biology laboratories.	Exact Sciences Exact Sciences is a company that provides cancer screening and diagnostic test products.	i2a i2a is a medical diagnostic company specializing in microbiology.	Trinity Biotech Trinity Biotech is a company that specializes in the development, manufacture, and marketing of diagnostic test kits.
Founding Date	Founding Date 1996	Founding Date 1995	Founding Date 1995	Founding Date 1988	Founding Date 1992
Type	Type Private	Type Private	Type Public	Type Private	Type Public
Tags	Tags Healthcare biotech medical diagnostics medtech	Tags Healthcare biotech medical diagnostics medtech	Tags Healthcare biotech medical diagnostics medtech	Tags Healthcare biotech medical diagnostics medtech	Tags Healthcare biotech medical diagnostics medtech
Locations	Locations Santa Marta de Tormes, ES HQ	Locations Paris, FR HQ	Locations Madison, US HQ Paris, FR Cologne, DE Milan, IT Tokyo, JP Baar, CH London, GB see more	Locations Montpellier, FR HQ	Locations Bray, IE HQ Jamestown, US
Employees	Employees 29	Employees 2223% increase	Employees 6,5003% increase	Employees 1413% increase	Employees 380
Valuation ($)	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 12.8 b	Valuation ($) N/A	Valuation ($) 19.1 m
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) $3.2b (FY, 2025)	Revenue (est.) N/A	Revenue (est.) $61.6m (FY, 2024)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods $984.2m (FY, 2025)	Cost of goods N/A	Cost of goods $38.2m (FY, 2024)
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit $2.3b (FY, 2025)	Gross profit N/A	Gross profit $23.3m (FY, 2024)
Net income	Net income N/A	Net income N/A	Net income ($207.9m) (FY, 2025)	Net income N/A	Net income ($31.2m) (FY, 2024)